Match!

Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes

Published on Mar 1, 2017in Kidney International8.306
· DOI :10.1016/j.kint.2016.09.038
Catherine M. Clase40
Estimated H-index: 40
(McMaster University),
Joshua I. Barzilay40
Estimated H-index: 40
(KP: Kaiser Permanente)
+ 6 AuthorsJohannes F.E. Mann42
Estimated H-index: 42
Abstract
Initiation of blockade of the renin-angiotensin system may cause an acute decrease in glomerular filtration rate (GFR): the prognostic significance of this is unknown. We did a post hoc analysis of patients with, or at risk for, vascular disease, in two randomized controlled trials: Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and the Telmisartan Randomized AssessmeNt Study in ACE iNtolerant participants with cardiovascular Disease (TRANSCEND), whose median follow-up was 56 months. In 9340 patients new to renin-angiotensin system blockade, who were then randomized to renin-angiotensin system blockade, a fall in GFR of 15% or more at 2 weeks after starting renin-angiotensin system blockade was seen in 1480 participants (16%), with persistence at 8 weeks in 700 (7%). Both acute increases and decreases in GFR after initiation of renin-angiotensin system blockade were associated with tendencies, mostly not statistically significant, to increased risk of cardiovascular outcomes, which occurred in 1280 participants, and of microalbuminuria, which occurred in 864. Analyses of creatinine-based outcomes were suggestive of regression to the mean. In more than 3000 patients randomized in TRANSCEND to telmisartan or placebo, there was no interaction between acute change in GFR and renal or cardiovascular benefit from telmisartan. Thus, both increases and decreases in GFR on initiation of renin-angiotensin system blockade are common, and may be weakly associated with increased risk of cardiovascular and renal outcomes. Changes do not predict increased benefit from therapy.
  • References (18)
  • Citations (17)
📖 Papers frequently viewed together
201727.60BMJ
36 Citations
162 Citations
594 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References18
Newest
#1Yuichiro Yano (NU: Northwestern University)H-Index: 45
#2Shouichi Fujimoto (University of Miyazaki)H-Index: 26
Last. Tsuyoshi Watanabe (Fukushima Medical University)H-Index: 27
view all 17 authors...
Whether long-term blood pressure (BP) variability among individuals without diabetes mellitus is associated with new-onset chronic kidney disease (CKD) risk, independently of other BP parameters (eg, mean BP, cumulative exposure to BP) and metabolic profile changes during follow-up, remains uncertain. We used data from a nationwide study of 48 587 Japanese adults aged 40 to 74 years (mean age, 61.7 years; 39% men) without diabetes mellitus or CKD (estimated glomerular filtration rate SBP (per 5 ...
31 CitationsSource
Rapid kidney function decline (RKFD) predicts cardiovascular morbidity and mortality, but serial assessment of estimated GFR (eGFR) is not cost-effective for the general population. Here, we evaluated the predictive value of albuminuria and three thresholds of dipstick proteinuria to identify RKFD in 2,574 participants in a community-based prospective cohort study with a median of 7 years follow-up. Median change in eGFR was −0.78 ml/min per 1.73 m2 per year; with 8.5% experiencing RKFD, defined...
44 CitationsSource
#1Frank A. Holtkamp (UMCG: University Medical Center Groningen)H-Index: 6
#2Dick de Zeeuw (UMCG: University Medical Center Groningen)H-Index: 88
Last. Hiddo J. Lambers Heerspink (UMCG: University Medical Center Groningen)H-Index: 45
view all 10 authors...
162 CitationsSource
#1Andrew S. Levey (Tufts University)H-Index: 129
#2Lesley A. Stevens (Tufts University)H-Index: 51
Last. Josef Coresh (Johns Hopkins University)H-Index: 131
view all 11 authors...
Background Equations to estimate glomerular filtration rate (GFR) are routinely used to assess kidney function. Current equations have limited precision and systematically underestimate measured GFR at higher levels.
9,213 CitationsSource
#2Koon K. TeoH-Index: 82
Last. Peter SleightH-Index: 93
view all 9 authors...
BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors reduce major cardiovascular events, but are not tolerated by about 20% of patients. We therefore assessed whether the angiotensin-receptor blocker telmisartan would be effective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage. METHODS: After a 3-week run-in period, 5926 patients, many of whom were receiving concomitant proven therapies, were randomised to receive telmisartan 80 mg/da...
726 CitationsSource
#1Johannes F. E. Mann (LMU: Ludwig Maximilian University of Munich)H-Index: 17
#2Roland E. SchmiederH-Index: 87
Last. Salim Yusuf Mb Bs DPhil Frcpc (Population Health Research Institute)H-Index: 214
view all 19 authors...
Summary Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination might be more effective than either treatment alone, but long-term data for comparative changes in renal function are not available. We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabete...
1,219 CitationsSource
#1Koon K. Teo (McMaster University)H-Index: 82
#2Janice Pogue (McMaster University)H-Index: 67
Last. Craig S. Anderson (USYD: University of Sydney)H-Index: 80
view all 7 authors...
Background In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes. Methods After a 3-week, single-blind run-in period, patients un...
2,582 CitationsSource
59 CitationsSource
Hemoglobin variability is the extent to which multiple measured hemoglobin values differ from each other. Variability may be assessed within the same patient or between patients in a group; in the context of clinical practice, it is generally the variability within a patient that is important,
22 CitationsSource
#1Giuseppe Remuzzi (Mario Negri Institute for Pharmacological Research)H-Index: 152
#2Norberto Perico (Mario Negri Institute for Pharmacological Research)H-Index: 75
Last. Piero Ruggenenti (Mario Negri Institute for Pharmacological Research)H-Index: 76
view all 4 authors...
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease The renin-angiotensin-aldosterone system (RAAS) is a well known regulator of blood pressure (BP) and determinant of target-organ damage. It controls fluid and electrolyte balance through coordinated effects on the heart, blood vessels, and Kidneys. Angiotensin II (AII) is the main effector of the RAAS and exerts its vasoconstrictor effect predominantly on the postglomerular arterioles, thereby increasin...
294 CitationsSource
Cited By17
Newest
Source
#1Didier Collard (UvA: University of Amsterdam)H-Index: 1
#2Tom F. Brouwer (UvA: University of Amsterdam)H-Index: 13
Last. Bert-Jan H. van den Born (UvA: University of Amsterdam)H-Index: 21
view all 6 authors...
Lowering blood pressure (BP) can lead to an initial decline in estimated glomerular filtration rate (eGFR). However, there is debate how much eGFR decline is acceptable. We performed a post hoc analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes-Blood Pressure) and SPRINT (Systolic Blood Pressure Intervention Trial), which randomized patients to intensive or standard systolic BP-targets. We determined the relation between initial decline in mean arterial pressure and eGFR. S...
1 CitationsSource
Erhohter Blutdruck bleibt eine Hauptursache von kardiovaskularen Erkrankungen, Behinderung und fruhzeitiger Sterblichkeit in Osterreich, wobei die Raten an Diagnose, Behandlung und Kontrolle auch in rezenten Studien suboptimal sind. Das Management von Bluthochdruck ist eine haufige Herausforderung fur Arztinnen und Arzte vieler Fachrichtungen. In einem Versuch, diagnostische und therapeutische Strategien zu standardisieren und letztendlich die Rate an gut kontrollierten Hypertoniker/innen zu erh...
Source
#2Yosuke SakaH-Index: 5
Last. Hidetomo NakamotoH-Index: 27
view all 10 authors...
Renin-angiotensin system inhibitors (RASIs), either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, are widely used in patients with non-dialysis chronic kidney disease, as a renin-angiotensin system (RAS) blockade has renoprotective effects. Several studies show that preserving residual renal function is important for a better prognosis in peritoneal dialysis (PD) patients. Here, we systematically reviewed the beneficial or harmful effects of RAS blockade in PD patien...
Source
#1Edouard Fu (KI: Karolinska Institutet)
#2Marco Trevisan (KI: Karolinska Institutet)H-Index: 5
Last. J. J. Carrero (KI: Karolinska Institutet)H-Index: 3
view all 9 authors...
Background and objectives Data from observational and interventional studies provide discordant results regarding the relationship between creatinine increase after renin-angiotensin system inhibition (RASi) and adverse outcomes. We compared health outcomes among patients with different categories of increase in creatinine upon initiation of RASi in a large population-based cohort. Design, setting, participants, & measurements We performed a retrospective analysis of the Stockholm CREAtinine Mea...
Source
#1Atsuhisa Sato (International University of Health and Welfare)H-Index: 3
Recently, deleterious effects of aldosterone on the kidney via mineralocorticoid receptors (MRs) have been noted. MR antagonists have been reported to show significant antialbuminuric effects when added to angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers. However, a decrease in the estimated glomerular filtration rate (eGFR) has been reported during MR antagonist treatment. On the other hand, although the eGFR often decreases, significant reductions in total mo...
Source
Source
#1Toshihiro SugiuraH-Index: 13
#2Fuyuko AkagakiH-Index: 1
Last. Aya NakamoriH-Index: 2
view all 4 authors...
Source
Source
2 CitationsSource